Acenxion Biosystems is transforming the landscape of diagnostic testing by delivering rapid antimicrobial susceptibility testing (AST) results to healthcare professionals, public health laboratories, hospitals, and clinics.
Traditionally, AST processes take several days, leaving doctors reliant on broad-spectrum antibiotics that may be ineffective.
Acenxion’s innovative technology can provide accurate AST results within just 4-6 hours, allowing clinicians to offer targeted treatments quickly, improving patient outcomes, and reducing healthcare costs.
Cutting diagnostic times with the fAST SystemTM
One of Acenxion’s flagship offerings, the Acenxion fAST SystemTM, delivers a complete Minimum Inhibitory Concentration (MIC) profile, even for challenging organisms such as Neisseria gonorrhoeae (NG).
This fully automated System can be integrated seamlessly into clinical workflows, making it a scalable option for institutions of all sizes.
Customisable antibiotic cassettes and real-time data reporting allow healthcare providers to develop effective treatment strategies swiftly, while the System’s small footprint ensures it can be implemented in a range of settings.
The fAST SystemTM offers significant improvements in antibiotic stewardship by enabling healthcare professionals to administer precise, effective treatments, avoiding the overuse of broad-spectrum antibiotics.
This technology protects the efficacy of antibiotics, helping to combat the global threat of antimicrobial resistance (AMR).
Combatting antimicrobial resistance: Why it matters
Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites evolve to resist the drugs designed to kill them, rendering treatments ineffective.
Over time, this leads to “superbugs” that no longer respond to existing medications, posing a severe risk to global health. AMR is driven by the overuse and misuse of antibiotics, often due to delays in accurate diagnosis, leading doctors to prescribe broad-spectrum treatments as a stopgap measure.
Unchecked, AMR could lead to infections that are impossible to treat, turning routine surgeries or minor injuries into life-threatening conditions.
To combat this, it’s essential to limit unnecessary antibiotic use by rapidly identifying the correct treatment through precise AST methods, like those provided by Acenxion Biosystems.
By delivering fast, conclusive results, Acenxion is helping to preserve the efficacy of antibiotics for future generations.
The future of diagnostics
With features such as custom data reporting for antibiotic stewardship programmes and advanced software solutions, Acenxion’s systems are designed to meet the evolving needs of modern healthcare.
Their innovative approach to diagnostics empowers healthcare professionals to make informed decisions swiftly, offering patients better outcomes and protecting global health from the growing threat of AMR.
